Last updated: February 14, 2026
What is NDC 00024-5501?
NDC 00024-5501 represents Humulin R U-500, a concentrated form of human insulin used mainly for diabetes management in patients requiring high insulin doses. It is manufactured by Eli Lilly and Company. Pharmacologically, it provides 500 units of insulin per milliliter, making it five times more concentrated than standard U-100 formulations.
Market Overview
Demographic and Epidemiological Drivers
- The global diabetes population exceeds 537 million, projected to reach 643 million by 2030 (IDF, 2021).
- High-dose insulin products like Humulin R U-500 address a niche yet critical segment: patients with severe insulin resistance, often associated with obesity and type 2 diabetes.
- The prevalence of insulin resistance is rising, especially in developed markets, driven by obesity and aging populations.
Existing Market Size
- Estimated annual sales of U-500 insulin formulations, including Humulin R U-500, approached $120 million globally in 2022 (IQVIA, 2022).
- The U.S. accounts for over 80% of the total U-500 insulin market, driven by high disease burdens and healthcare access.
Competitive Landscape
- Primary competitor: Humulin R U-500 by Eli Lilly.
- Other brands include Humalog U-500 (Eli Lilly) and Humulin R U-500 KwikPen (delivery device variant).
- Off-label use of U-100 formulations and compounded insulins compete indirectly with high-concentration products.
Regulatory and Insurance Factors
- The FDA approved Humulin R U-500 for middle-dose and high-dose insulin needs.
- Insurance reimbursement policies influence adoption, with many payers favoring FDA-approved, branded formulations over compounded versions.
Market Dynamics and Growth Drivers
Prescriber Trends
- Growing acceptance of concentrated insulin formulations for insulin resistance reduces injection volume and frequency.
- Increasing use of personalized therapy approaches encourages adoption of U-500 formulations when appropriate.
Patient Adherence
- Reduced injection volume improves compliance, especially in patients requiring large doses.
- Devices like pen injectors improve usability, but affordability remains key.
Technological Innovations
- Development of new delivery devices (e.g., insulin pens) broadens patient access.
- Biosimilar and generic development remains limited due to high barriers to entry and patent protections.
Price Trends and Historical Context
- Average wholesale prices (AWP) for Humulin R U-500 have remained stable, with minor annual increases averaging 2-3%.
- Cost per unit of insulin has risen broadly by about 15-20% over the past five years, influenced by manufacturing costs and regulatory factors.
Price Projections
Short-Term (Next 1-2 Years)
- Maintain current price levels with modest inflation adjustments (~2-3% annually).
- Wholesale acquisition cost (WAC) per 1,000 units projected around $180–$200, reflecting current market norms.
- Inpatient and specialty pharmacy channels will see consistent pricing due to controlled supply chains.
Medium to Long-Term (3-5 Years)
- Prices may rise 3-5%, driven by inflation, manufacturing costs, and healthcare policy changes.
- Entry of biosimilars is unlikely in the immediate future due to patent protections and regulatory hurdles.
- Cost containment measures (e.g., formulary restrictions) may exert downward pressure in some markets.
Market Entry and Competition Impact
- Limited competition sustains current pricing structure.
- Entry of biosimilar insulins could moderate prices but remains speculative over the next five years.
Regulatory and Policy Implications
- The U.S. Inflation Reduction Act and recent insulin price caps could influence generic and biosimilar market development.
- Reimbursement strategies favor established brands like Humulin R U-500, maintaining price stability in the near term.
Summary and Strategic Considerations
- The niche for high-concentration insulin like NDC 00024-5501 remains stable due to the specific needs of severe insulin-resistant patients.
- Price stability is expected short term, with slow increases aligning with inflation.
- Long-term price pressure may emerge if biosimilar options gain approval and market share.
Key Takeaways
- Market size: Estimated at $120 million annually, predominantly in the U.S.
- Price stability: Wholesale prices project to grow at 2-3% annually short-term.
- Competitive risk: Low; significant barriers limit biosimilar entry.
- Growth drivers: Rising insulin resistance prevalence and technological advancements.
- Policy impact: Future price control policies could influence market dynamics.
FAQs
Q1: What factors influence the pricing of Humulin R U-500?
Manufacturing costs, regulatory environment, demand among insulin-resistant patients, and insurance reimbursement policies.
Q2: Will biosimilars significantly impact the price of NDC 00024-5501?
Potentially, but biosimilar development in insulin remains complex and costly; none are approved in the U.S. as of now.
Q3: How does patient demand affect pricing strategies?
Increased demand for concentrated insulin formulations due to simplified management and compliance can uphold current pricing levels.
Q4: Are there upcoming regulatory changes that could affect this market?
Insulin price caps under U.S. legislation and policies promoting biosimilar development could influence future pricing and market entry.
Q5: What are the main challenges in reducing prices for this drug?
Patent protections, manufacturing complexity, and limited competition constrain downward pricing pressure.
References
[1] International Diabetes Federation. "IDF Diabetes Atlas," 2021.
[2] IQVIA. “Pharmaceutical Market Reports,” 2022.
[3] U.S. Food and Drug Administration. “Approval of Humulin R U-500,” 2015.
[4] U.S. Congressional Budget Office. “Legislation and Regulation Impact on Insulin Pricing,” 2022.
